Similar articles

• Antiretroviral use during pregnancy for treatment or prophylaxis.

  Sturt AS, Read JS. Sturt AS, et al. Expert Opin Pharmacother. 2011 Aug;12(12):1875-85. doi: 10.1517/14656566.2011.584062. Epub 2011 May 3. Expert Opin Pharmacother. 2011. PMID: 21534886 Review.
• Recommendations for human immunodeficiency virus screening, prophylaxis, and treatment for pregnant women in the United States.

  Jamieson DJ, Clark J, Kourtis AP, Taylor AW, Lampe MA, Fowler MG, Mofenson LM. Jamieson DJ, et al. Am J Obstet Gynecol. 2007 Sep;197(3 Suppl):S26-32. doi: 10.1016/j.ajog.2007.03.087. Am J Obstet Gynecol. 2007. PMID: 17825647
• How many MSM in Europe could benefit from PrEP--a 9 billion Euro question?

  Kenyon CR, Osbak K. Kenyon CR, et al. Int J STD AIDS. 2015 Nov;26(13):988-90. doi: 10.1177/0956462415584490. Int J STD AIDS. 2015. PMID: 26490178 No abstract available.
• HIV pre-exposure prophylaxis (PrEP).

  Tumarkin E, Siedner MJ, Bogoch II. Tumarkin E, et al. BMJ. 2019 Jan 17;364:k4681. doi: 10.1136/bmj.k4681. BMJ. 2019. PMID: 30655299 No abstract available.
• Antiretrovirals for primary HIV prevention: the current status of pre- and post-exposure prophylaxis.

  Krakower DS, Jain S, Mayer KH. Krakower DS, et al. Curr HIV/AIDS Rep. 2015 Mar;12(1):127-38. doi: 10.1007/s11904-014-0253-5. Curr HIV/AIDS Rep. 2015. PMID: 25600106 Free PMC article. Review.